USA Genome Sequencing Market Analysis, 2020

Decreasing Cost of Sequencing Leading to the Growth of the USA Genome Sequencing Market During 2020-25

USA Genome Sequencing Market Analysis, 2020 research report depicts a deep-dive market analysis of statistics of USA Genome Sequencing market which consists of regional market size, market forecast, CAGR market segmentation, market shares of diverse regions and countries, market share of various end users, applications, product type, technologies, competitive benchmarking, etc.

According to this research report titled “USA Genome Sequencing Market Analysis, 2020”, the USA Genome Sequencing market is anticipated to grow at a considerable CAGR during 2020-25F on an account of bolstering investment in genomics medicine and rising partnerships among the market players to accelerate the adoption of genomics in order to support the increasing demand for clinical grade genomic information at lower cost.

Market Segmentation

Sequencing by Synthesis to Dominate

Based on Technology, Sequencing by Synthesis is estimated to dominate the market by 2025. The growth is attributed to it is widely used in sequencing protocol by many of the DNA sequencing platforms. Moreover, robust developments in technology are dramatically reducing costs is projected to promulgate the market growth of Genome Sequencing market in the near future as stated in the research report “USA Genome Sequencing Market Analysis, 2020”.

Academic & Government Research Institute Accounted the Substantial Market Share

Based on End User, Academic & Government Research Institute segment acquired the significant market share in 2019 as genome sequencing is widely used for practical implementation of data analysis in academic and government research institutes due to dominance of a large number of research and development projects.

Market Opportunities

The market growth of the genome sequencing is attributed to launch of innovative sequencing systems by the key players, escalating demand for a platform to support deeper sequencing and rising clinical adoption of genome sequencing in rare and undiagnosed genetic diseases. Moreover, the escalating number of patients with chronic diseases, declining cost of sequencing, along with surging government funding for health research in sequencing and also to establish genome centers are some of the factors for the growth of the market in the near future.

Impact of COVID-19

COVID-19 has led to the growth of genome sequencing as it is used to efficiently understand COVID-19 and its spread. Moreover, the sequencing helps the researches to understand coronavirus adapts to its human host and its impact on the vaccines and drug treatments which can be discovered in the near future through monitoring the virus.

Competitive Landscape

According to the publisher, the key players with a considerable market share in the USA Genome Sequencing market include Abbott, Roche, Agilent, Perkinelmer, Siemens, Illumina, ThermoFisher, Pacific Biosciences, Integrated DNA Technologies, Cytiva etc.

Key Questions Answered in the Market Research Report

1. What are the key overall market statistics or market estimates (Market Overview, Market Size- By Value, Forecast Numbers, Market Segmentation, Market Shares) of USA Genome Sequencing Market?
2. What is the region wise industry size, growth drivers and challenges key market trends?
3. What are the key innovations, technology upgrades, opportunities, regulations in the USA Genome Sequencing Market?
4. Who are the key competitors or market players and how they perform in USA Genome Sequencing Market based on competitive benchmarking matrix?
5. What are the key results derived from the market surveys conducted during the course of USA Genome Sequencing Market study?

1. Introduction

1.1. Product Definition
1.2. Research Process
1.3. Market Segmentation
1.4. Assumptions

2. Executive Summary3. The US Genome Sequencing Market Start-Up Ecosystem4. Impact of COVID-19 on The US Genome Sequencing Market5. Expert Verbatim-Interview Excerpts of industry experts

6. The US Genome Sequencing Market Outlook, 2015-2025F

6.1. Market Size & Analysis
6.1.1. Revenues
6.2. Market Share & Analysis
6.2.1. By Product
6.2.1.1. Consumables
6.2.1.2. Instruments
6.2.1.3. Services
6.2.2. By Technology
6.2.2.1. Sequencing By Synthesis
6.2.2.2. Ion Semiconductor Sequencing
6.2.2.3. Pyrosequencing
6.2.2.4. Sequencing By Ligation
6.2.2.5. Chain Termination Technology
6.2.2.6. Single-Molecule Real-Time Sequencing
6.2.2.7. Nanopore Sequencing
6.2.2..8. Others
6.2.3. By Application
6.2.3.1. Biomarker & Cancer
6.2.3.2. Personalized medicine
6.2.3.3. Forensic
6.2.3.4. Reproductive Health
6.2.3.5. Diagnostics
6.2.3.6. Others
6.2.4. By End User
6.2.4.1. Hospitals & Clinics
6.2.4.2. Academic & government research institute
6.2.4.3. Biotechnology & Pharmaceutical Companies
6.2.5. By Region
6.2.5.1. South
6.2.5.2. West
6.2.5.3. Midwest
6.2.5.4. Northeast
6.2.5.5. Others
6.2.6. By Company
6.2.6.1. Market Shares, By Revenue
6.2.6.2. Strategic Factorial Indexing
6.2.6.3. Competitor Placement in MarkNtel Quadrant
6.3. Market Attractiveness Index
6.3.1. By Product
6.3.2. By Technology
6.3.3. By Application
6.3.4. By End User
6.3.5. By Region

7. The US Genome Sequencing Market Policies, Regulations, Product Standards8. The US Genome Sequencing Market Trends & Insights

9. The US Genome Sequencing Market Dynamics

9.1. Growth Drivers
9.2. Challenges
9.3. Impact Analysis

10. The US Genome Sequencing Market Hotspot & Opportunities11. The US Genome Sequencing Market Key Strategic Imperatives for Success & Growth

12. Competition Outlook

12.1. Competition Matrix
12.1.1. Product Portfolio
12.1.2. Target Markets
12.1.3. Target End User
12.1.4. Research & Development
12.1.5. Strategic Alliances
12.1.6. Strategic Initiatives
12.2. Company Profiles of Top Companies (Business Description, Product Segments, Business Segments, Financials, Strategic Alliances/ Partnerships, Future Plans)
12.2.1. Abbott
12.2.2. Roche
12.2.3. Agilent
12.2.4. Perkinelmer
12.2.5. Siemens
12.2.6. Illumina
12.2.7. ThermoFisher
12.2.8. Pacific Biosciences
12.2.9. Integrated DNA Technologies
12.2.10. Cytiva

13. Disclaimer